News und Analysen

There are plenty of attractive stocks on the market. Some, though, have significantly underperformed their growth potential this year, making them attractive at their current levels.

This list

A lot of money has been spent on setting up artificial intelligence (AI) infrastructure in the past three years, and it looks like the spending spree will continue. AI pioneer Nvidia recently

Dyne Therapeutics (NASDAQ: DYN) had a Monday neither it nor its investors will ever forget. This wasn't of its own making, however, as a premium-priced buyout of a peer was attracting serious

A richly priced buyout seriously boosted the share price of biotech Avidity Biosciences (NASDAQ: RNA) as the stock trading week began. The company's equity rose by 42%, closing to land just below

Share prices of Advanced Micro Devices (NASDAQ: AMD) soared to new highs recently on news of a transformative deal to supply chips for ChatGPT maker OpenAI. The surge in the share price comes ahead

The S&P 500 index was recently offering a tiny dividend yield of 1.2%. You can get as much as 7% from some of the world's largest drugmakers. But sometimes, a high yield is a sign of risk.

What does

One struggling pharma stock that could use a boost from a strong earnings report is Pfizer (NYSE: PFE). The company's valuation has plummeted in recent years as patent cliffs and question marks

If you are looking for a healthcare stock to add to your portfolio as October draws to a close, consider Intuitive Surgical (NASDAQ: ISRG), Merck (NYSE: MRK), and Johnson & Johnson (NYSE: JNJ). Each

Nvidia (NASDAQ: NVDA) is transforming from a graphics processing unit (GPU) champion to an artificial intelligence (AI) infrastructure cash engine. Learn about Blackwell, DGX Spark, and DGX Cloud

Intuitive Surgical (NASDAQ: ISRG) has dominated the market for robotic-assisted surgery (RAS) devices for the better part of the last 20 years, with little competition to speak of in many of the

Being a big company comes with a lot of positives. But there are negatives, too. Some businesses end up imploding under their own weight because they face increased scrutiny and competition and

What if you had invested in any of the current leaders in the biotech industry before they established themselves as such? You'd have earned terrific returns. While we can't go back in time to do

Vertex Pharmaceuticals (NASDAQ: VRTX) and Pfizer (NYSE: PFE) are both among the largest drugmakers in the world. The latter currently has the edge in this department, with a market cap of $141

A big dividend yield is nice to see, but it shouldn't be the only thing you look at when buying a stock. The actual business behind the yield is, in fact, more important. That's why you'll need to

On Friday, Pennsylvania-based Conestoga Capital Advisors disclosed selling 855,435 shares of Vertex (NASDAQ:VERX), an estimated $24.8 million transaction based on average prices in the third

There's been some choppy activity in the stock market in October as the intensifying trade war between the U.S. and China has rattled investors. But the outlook for growth in the technology sector

UnitedHealth Group (NYSE: UNH) has been a top dividend stock to own for years. It has consistently provided investors with a reliable dividend, and it has made generous increases to the payout over

Dividend investors shouldn't be dissuaded from investing just because the S&P 500 (SNPINDEX: ^GSPC) has a miserly 1.2% yield. If you dig in a bit, you can find attractive dividend stocks, including

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can

It isn't all that difficult to find high-yield dividend stocks -- say, those paying out at more than 4%. The real trick is finding a company that produces sufficient profitability and free cash flow

Explore the exciting world of Summit Therapeutics (NASDAQ: SMMT) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights

Dividend stocks are arguably worth a premium in the current environment. Between a prolonged government shutdown and President Donald Trump's trade wars, the economy and the market might be heading